Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 16/20 | 0.77 |
| ▸ | PDE1A | P54750 | 3/20 | 0.77 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.77 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.77 |
| ▸ | HPGD | P15428 | 1/20 | 0.77 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.61 |
| ▸ | PDE6C | P51160 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | ABCC5 | O15440 | 1/20 | 0.50 |
| ▸ | PDE6D | O43924 | 1/20 | 0.50 |
| ▸ | PDE8A | O60658 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5462416 | 0.93 | PDE5A (0.67) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6716451 | 0.92 | PDE5A (0.66) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL5445759 | 0.90 | PDE5A (0.63) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6716572 | 0.90 | PDE5A (0.63) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL5459779 | 0.88 | PDE5A (0.64) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL6715674 | 0.88 | PDE5A (0.61) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL1202 | 0.87 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL31174349 | 0.87 | PDE5A (1.00) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL5450370 | 0.82 | KMT2A (0.71) | PDE5APDE1APDE1BPDE1CKMT2A | |
| SCHEMBL28890961 | 0.82 | KMT2A (0.71) | PDE5APDE1APDE1BPDE1CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221825-B2 | Pyrazolopyrimidinone compound and imidazo triazone compound for treating erectile dysfunction | ZHEJIANG DADE PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-9221825-B2 | Pyrazolopyrimidinone compound and imidazo triazone compound for treating erectile dysfunction | ZHEJIANG DADE PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-9221825-B2 | Pyrazolopyrimidinone compound and imidazo triazone compound for treating erectile dysfunction | ZHEJIANG DADE PHARMACEUTICAL GROUP CO., LTD. (CN) | 2015-12-29 | — | — | US | disclosed |
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | Zhejiang Date Pharmaceutical Group Co. Ltd (CN) | 2014-01-16 | — | — | US | disclosed |
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | Zhejiang Date Pharmaceutical Group Co. Ltd (CN) | 2014-01-16 | — | — | US | disclosed |
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | Zhejiang Date Pharmaceutical Group Co. Ltd (CN) | 2014-01-16 | — | — | US | disclosed |
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | THE INSTITUTE OF RADIATION MEDICINE, ACADEMY OF MILITARY MEDICAL SCIENCES, PLA (CN) | 2007-09-20 | — | — | US | disclosed |
| EP-1695976-A1 | PYRAZOLOPYRIMIDINETHIONE DERIVATIVES, SALTS AND SOLVATES THEREOF, PREPARATION METHODS AND USE THEREOF | Institute of Radiation Medicine Academy of Military Medical Sciences of the Pla (CN) | 2006-08-30 | — | — | EP | disclosed |
| EP-1395593-A4 | NOVEL PYRAZOLOPYRIMIDINETHIONE DERIVATIVES. PREPARATION METHODS THEREOF AND THEIR USE AS THERAPEUTICS FOR ERECTILE DYSFUNCTION | KOREA INST SCI & TECH (KR) | 2004-11-10 | — | — | EP | disclosed |
| US-20040176371-A1 | Novel pyrazolopyrimidinethione derivatives, preparation methods thereof and their use as therapeutics for erectile dysfunction | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-09-09 | — | — | US | disclosed |
| EP-1395593-A1 | NOVEL PYRAZOLOPYRIMIDINETHIONE DERIVATIVES. PREPARATION METHODS THEREOF AND THEIR USE AS THERAPEUTICS FOR ERECTILE DYSFUNCTION | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-03-10 | — | — | EP | disclosed |
| WO-2002102802-A1 | NOVEL PYRAZOLOPYRIMIDINETHIONE DERIVATIVES. PREPARATION METHODS THEREOF AND THEIR USE AS THERAPEUTICS FOR ERECTILE DYSFUNCTION | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219220-A1 | Pyrazolopyrimidinethione Derivatives, Salts and Solvates Thereof, Preparation Methods and Use Thereof | PDE5A, PDE3B, PDE3A | PDE5A 1/4885PDE1A 33/4885PDE1B 16/4885 |
| US-20140018351-A1 | Pyrazolopyrimidinone Compound and Imidazo Triazone Compound for Treating Erectile Dysfunction | PDE3A, PDE3B, PDE5A | PDE5A 3/4885PDE1A 16/4885PDE1B 23/4885 |
| US-20040176371-A1 | Novel pyrazolopyrimidinethione derivatives, preparation methods thereof and their use as therapeutics for erectile dysfunction | PDE3B, PDE3A, PDE5A | PDE5A 3/4885PDE1A 217/4885PDE1B 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.